Fasenra
(Benralizumab)ApprovedMonoclonal antibody
AstraZenecaBenralizumab is used to treat a specific type of asthma (eosinophilic asthma) in people whose symptoms aren't well controlled with other asthma medications. It works by reducing certain white blood cells in the body that contribute to airway inflammation.[2] Fasenra is currently approved and in use across 9 indications[4].[1]
Fasenra is one of 90 biologic programs targeting Asthma. It is currently in Approved.
9
Indications
71
Total Trials
14
Active Trials
89
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
175 competitors in Asthma
#DrugCompanyPhaseTrials
1Fasenra
AstraZenecaApproved
Celexa
AbbViePreclinical
Arcoxia
NovartisPreclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
DUPIXENT
RegeneronPreclinical
Paracetamol
GSKPreclinical
Blood Withdrawn
Emergent BioSolutionsPreclinical
Aclidinium Bromide
AstraZenecaPreclinical
Atrovent
Boehringer IngelheimPreclinical
Blood Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Asthma25 trials
Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI
Active, not recruiting·—·N/A·NCT03733535·29 enrolled
Show 22 more trials
Interaction Between Benralizumab and Basophils in Eosinophilic Asthma
Completed·IInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz··NCT04742504·20 enrolled
Similarities and Differences of Biological Therapies for Severe Asthma.
Unknown status·—··NCT04665141·600 enrolled
BenRalizumab Effect on Airway Remodeling in Severe asTHma
Recruiting·—·Phase 4·NCT06288516·45 enrolled
Chronic Obstructive Pulmonary Disease5 trials
Chronic Rhinosinusitis2 trials
Function2 trials
Eosinophilic Gastritis2 trials
Benralizumab for Eosinophilic Gastritis (BEGS)
Completed·—·Phase 2/3·NCT03473977·26 enrolled
30 more indications
Atopic Dermatitis2 trials
Hypereosinophilic syndrome2 trials
Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome
Unknown status·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2/3·NCT02130882·20 enrolled
Severe Eosinophilic Asthma2 trials
Granulomatosis with Polyangiitis1 trial
ESS1 trial
Cystic Fibrosis1 trial
Efficacy and Safety1 trial
Safety and Efficacy1 trial
Chronic Rhinosinusitis With Nasal Polyps1 trial
Chronic Spontaneous Urticaria1 trial
Atopic Asthma1 trial
Breast Cancer1 trial
Bullous Pemphigoid1 trial
Influenza1 trial
Inflammation1 trial
Side Effects1 trial
Urticaria1 trial
Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody
Completed·—·Phase 4·NCT03183024·12 enrolled
Nasal polyposis1 trial
Targeted Therapy1 trial
Monoclonal1 trial
Eosinophilic Granulomatosis With Polyangiitis (EGPA)1 trial
Eosinophilic Granulomatous Vasculitis1 trial
Regulatory
FDA Approval Timeline[5]
Nov 14, 2017
FASENRA
BLA BLA761070
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Fasenra drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Benralizumab. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Interleukin-5 Receptor Subunit Alpha Inhibitor[3]
- Modality
- Monoclonal antibody[3]
- Highest Phase
- Approved[1]
- Company